Breast Cancer

Heather Lynn McArthur, MD, MPH, discusses key factors considered in the optimal sequencing of first and second line treatment option in patients with advanced triple-negative breast cancer.

Nathalie McDowell Johnson, MD, FACS, discusses the accuracy of genomic testing in Black women with estrogen receptor-positive breast cancer.

Laura J. Esserman, MD, MBA, discusses the effect early end points could have for clinical trials in breast cancer, how these end points could help usher in more individually tailored treatment options based on an individual patient’s disease and response, and how early end points have been used in the ongoing phase 2 I-SPY 2 trial.

William M. Sikov, MD, discusses the benefit of CDK4/6 inhibitors in the treatment of hormone receptor–positive/HER2-negative breast cancers.

Blueprint Medicines announced on March 28, 2023, that the FDA has removed a partial clinical hold on the phase 1/2 VELA trial trial of BLU-222.

The combination of ribociclib and endocrine therapy (ET) significantly reduced the risk of disease recurrence vs standard adjuvant ET in patients with hormone receptor–positive/HER2-negative early breast cancer at risk of recurrence.

Japan’s Ministry of Health, Labor and Welfare has approved fam-trastuzumab deruxtecan-nxki for the treatment of adult patients with HER2-low unresectable or recurrent breast cancer after prior chemotherapy.

Lisa A. Carey MD, ScM, FASCO, discusses the varying approaches to response-guided therapy in HER2-positive breast cancer.

Total ablation of all metastases in addition to standard systemic therapy did not improve progression-free survival or overall survival compared with standard systemic therapy alone in patients with oligometastatic breast cancer.

Kevin Kalinsky, MD, MS, discusses genetic sequencing in triple-negative breast cancer, the significance of breast cancer tumor board discussions for informing further research and optimizing patient care, and how future directions in breast cancer treatment are building off the current benefits of drugs classes like antibody-drug conjugates.

Susan Domchek, MD, FASCO, discusses the importance of germline testing in breast cancer care.

A new drug application seeking the approval of Lumisight, an optical imaging agent that detects cancerous tissue during initial lumpectomy to allow for a more complete resection, has been submitted to the FDA.

Ruth M. O’Regan, MD, discusses how results from the phase 2 RIGHT Choice trial could influence the treatment paradigm in hormone receptor–positive, HER2-negative breast cancer.

Roadblocks such as PARP inhibitor resistance have resulted in an unmet need and uncertain optimal identification concerning patients who would elicit the most benefit from homologous recombination deficiency–directed therapies.

Patritumab deruxtecan elicited responses in previously treated patients with EGFR-mutated metastatic or unresectable non–small cell lung cancer and patients with HER3-expressing metastatic breast cancer.

RBN-2397, a PARP7 inhibitor, was found to be well tolerated and have preliminary antitumor activity as monotherapy in patients with advanced solid tumors, including head and neck squamous cell carcinoma, breast cancer, and squamous cell carcinoma of the lung.

Jean Wright, MD, discusses the benefit of moderate hypofractionation in patients for adjuvant radiotherapy in patients with early-stage breast cancer.

Steven Cai, MD, FACS, discusses the ongoing effort to address disparities in breast cancer care, and the importance of improving access to care for underserved patients.

Hyman B. Muss, MD, discusses the use of metronomic chemotherapy in metastatic breast cancer.

Closing out their discussion on HR+ breast cancer management, expert panelists share their excitement for the evolving treatment paradigm.

Priyanka Sharma, MD, discusses updates in optimal systemic therapy strategies in early-stage triple-negative breast cancer.

Rima Patel, MD, discusses the associations between the 21-gene oncotype DX recurrence score, Ki-67, and race in early-stage breast cancer.

David D'Ambrosio, MD, discusses the benefit of utilizing adjuvant accelerated partial breast irradiation, as well as a phase 2 trial investigating robotic stereotactic adjuvant accelerated partial breast irradiation for hormone receptor–positive, postmenopausal, early-stage breast cancer.

David Rimm, MD, PhD, discusses both the use and advantages of utilizing multiplex spatial proteomic profiling in breast cancer.

Nathalie McDowell Johnson, MD, FACS, discusses the importance of diverse representation in breast cancer clinical trials.

Virginia Kaklamani, MD, discusses the utilization of elacestrant following treatment with CDK4/6 inhibitors in patients with estrogen receptor-positive, HER2-negative metastatic breast cancer.

Nita Nair, MBBS, DNB, MCh, discusses research evaluating the role of yoga as a way to improve the quality of life of patients undergoing breast cancer treatments.

Comprehensive discussion on novel treatment modalities in HR+ metastatic breast cancer and insight to when it is appropriate to select these agents.

Shared insight on the selection of endocrine partners while managing patients in the relapsed/refractory setting of HR+ metastatic breast cancer.

Palbociclib plus an aromatase inhibitor improved real-world data for progression-free survival, overall survival, and time to chemotherapy compared with an aromatase inhibitor alone in patients 75 years and older with hormone receptor–positive, HER2-negative advanced/metastatic breast cancer.